ValiRx Past Earnings Performance
Past criteria checks 0/6
ValiRx has been growing earnings at an average annual rate of 3.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 95.1% per year.
Key information
3.5%
Earnings growth rate
72.9%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 95.1% |
Return on equity | -58.9% |
Net Margin | -20,554.0% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How ValiRx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -2 | 2 | 0 |
31 Mar 24 | 0 | -2 | 2 | 0 |
31 Dec 23 | 0 | -2 | 2 | 0 |
30 Sep 23 | 0 | -2 | 2 | 0 |
30 Jun 23 | 0 | -2 | 2 | 1 |
31 Mar 23 | 0 | -2 | 2 | 1 |
31 Dec 22 | 0 | -2 | 2 | 1 |
30 Sep 22 | 0 | -2 | 2 | 0 |
30 Jun 22 | 0 | -2 | 2 | 0 |
31 Mar 22 | 0 | -2 | 2 | 0 |
31 Dec 21 | 0 | -2 | 1 | 0 |
30 Sep 21 | 0 | -1 | 1 | 0 |
30 Jun 21 | 0 | -1 | 1 | 0 |
31 Mar 21 | 0 | -1 | 1 | 0 |
31 Dec 20 | 0 | -1 | 1 | 0 |
30 Sep 20 | 0 | -2 | 2 | 1 |
30 Jun 20 | 0 | -2 | 2 | 1 |
31 Mar 20 | 0 | -2 | 2 | 1 |
31 Dec 19 | 0 | -2 | 2 | 1 |
30 Sep 19 | 0 | -3 | 2 | 1 |
30 Jun 19 | 0 | -3 | 2 | 1 |
31 Mar 19 | 0 | -4 | 2 | 1 |
31 Dec 18 | 0 | -4 | 3 | 2 |
30 Sep 18 | 0 | -4 | 2 | 2 |
30 Jun 18 | 0 | -3 | 2 | 2 |
31 Mar 18 | 0 | -3 | 2 | 2 |
31 Dec 17 | 0 | -3 | 1 | 2 |
30 Sep 17 | 0 | -4 | 2 | 2 |
30 Jun 17 | 0 | -5 | 2 | 2 |
31 Mar 17 | 0 | -5 | 2 | 2 |
31 Dec 16 | 0 | -5 | 2 | 2 |
30 Jun 16 | 0 | -3 | 1 | 1 |
31 Mar 16 | 0 | -2 | 1 | 1 |
31 Dec 15 | 0 | -2 | 1 | 2 |
30 Sep 15 | 0 | -3 | 2 | 2 |
30 Jun 15 | 0 | -3 | 2 | 2 |
31 Mar 15 | 0 | -3 | 2 | 2 |
31 Dec 14 | 0 | -3 | 2 | 2 |
30 Sep 14 | 0 | -3 | 1 | 2 |
30 Jun 14 | 0 | -2 | 1 | 1 |
31 Mar 14 | 0 | -3 | 1 | 1 |
31 Dec 13 | 0 | -3 | 1 | 2 |
Quality Earnings: EAJF is currently unprofitable.
Growing Profit Margin: EAJF is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EAJF is unprofitable, but has reduced losses over the past 5 years at a rate of 3.5% per year.
Accelerating Growth: Unable to compare EAJF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EAJF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Return on Equity
High ROE: EAJF has a negative Return on Equity (-58.92%), as it is currently unprofitable.